Oncolytics Biotech (TSE:ONC) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s share price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares changing hands.

Oncolytics Biotech Price Performance

The company has a debt-to-equity ratio of 14.58, a current ratio of 2.88 and a quick ratio of 8.86. The business’s fifty day moving average price is C$14.90 and its 200-day moving average price is C$14.90. The stock has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.